Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments.

Our main office is located in Tromsø and through our continued collaboration with the University of Tromsø we have access to state-of-the-art laboratories and staff with extensive experience of developing peptide based drugs, including preparation of peptidomimetics. Business and product development is driven from our subsidiary office in Oslo.

The company has received substantial grants from the Norwegian Research Council through the MEDKAP, FUGE and BIA programs to support R&D efforts in both our therapeutic areas. Our equity fundraising has been very successful, each time heavily oversubscribed.